Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICAM3 siRNA
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
ICAM3 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of intercellular adhesion molecule 3 (ICAM3, also known as CD50). ICAM3 is an inflammation-related cell adhesion molecule that has been implicated in maintaining cancer stem cell (CSC) stemness, promoting cell migration, and mediating chemoresistance in various malignant tumors, including breast and lung cancers. In preclinical research, knockdown of ICAM3 using siRNA has been shown to inhibit sphere formation, decrease the aldehyde dehydrogenase-positive (ALDH+) subpopulation, reduce side populations, and suppress tumor growth and metastasis in vivo. ICAM3 siRNA is primarily utilized as a research reagent to investigate the role of ICAM3 and its downstream signaling pathways, such as the Src/PI3K/Akt cascade, in tumor progression and stemness.
- Other names
- ICAM-3 siRNAICAM3 siRNAICAM 3 siRNAICAM3 small interfering RNAICAM-3 small interfering RNAICAM 3 small interfering RNAintercellular adhesion molecule 3 siRNA
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)POU5F1 (Octamer-binding transcription factor 4)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)ICAM3 (ICAM-3)SOX2 (SRY-box transcription factor 2)
Beyond the preview
Go deeper on ICAM3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICAM3 siRNA.